Eli Lilly stock slides after FDA pushes obesity pill decision to April 10
Eli Lilly shares fell 3.8% to $1,032.97 in after-hours trading after the FDA delayed its decision on the company’s obesity pill to April 10. A Texas compounding pharmacy filed a new lawsuit against Lilly and Novo Nordisk, alleging efforts to block access to cheaper alternatives. Investors are watching Lilly’s Feb. 4 earnings call and the FDA’s April decision as key dates.